公开(公告)号：US12133866B2

公开(公告)日：2024-11-05

申请号：US17735146

申请日：2022-05-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Yaki Eidelstein ,  Eran Ophir ,  Assaf Lask ,  Ran Afik ,  Noga Or-Geva ,  Esther Bachar-Lustig

IPC: A61K35/17 ,  A61K35/12 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/00 ,  C12N5/0783

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US10933122B2

公开(公告)日：2021-03-02

申请号：US16521622

申请日：2019-07-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: C12N9/64 ,  A61K38/48

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US10426821B2

公开(公告)日：2019-10-01

申请号：US15636683

申请日：2017-06-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: C12N9/64 ,  A61K38/48

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US09764008B2

公开(公告)日：2017-09-19

申请号：US14398754

申请日：2013-05-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: A61K38/54 ,  A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US20150132281A1

公开(公告)日：2015-05-14

申请号：US14398754

申请日：2013-05-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

Abstract translation: 公开了一种治疗炎性疾病的方法。 该方法包括向受试者施用治疗有效量的包含TNF-α转换酶（TACE）的前域的多肽，所述多肽缺乏所述TACE的催化结构域，所述多肽在所选择的位点包含修饰 来自由R58，R56和K57组成的组，其使所述多肽对弗林蛋白酶降解具有抗性，所述多肽能够下调TACE的活性，从而治疗炎性疾病。

公开(公告)号：US11324777B2

公开(公告)日：2022-05-10

申请号：US15825275

申请日：2017-11-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Yaki Eidelstein ,  Eran Ophir ,  Assaf Lask ,  Ran Afik ,  Noga Or-Geva ,  Esther Bachar-Lustig

IPC: A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K35/12

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.